Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET

Company Participants

Lindsey Allen - Head, IR & Communications
Justin Klee - Co-CEO
Camille Bedrosian - CMO
Jim Frates - CFO
Josh Cohen - Co-CEO

Conference Call Participants

Corinne Jenkins - Goldman Sachs
Graig Suvannavejh - Mizuho

Operator

Good morning. My name is Morgan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please limit your questions to one with one follow-up. If you have additional questions, you may rejoin the queue. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to your host, Lindsey Allen, Head of Investor Relations and Communications. Please proceed.

Lindsey Allen

Good morning, and thank you for joining us today to discuss our first quarter 2024 Financial results. With me on the call are Josh Cohen and Justin Klee, our Co-CEOs; Jim Frates, our Chief Financial Officer; and Dr. Camille Bedrosian, our Chief Medical Officer.

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are made based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our plans with respect to AMX0035 and AMX0114, statements regarding current and planned clinical trials, statements regarding regulatory developments and the expected timing thereof, our business strategy and outlook, and our expected financial performance and cash runway.

Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and Amylyx disclaims any obligation to update such statements unless required by law.

Now I will turn the call over to Justin.

Justin Klee

Good morning, and thank you all for joining us today. The first quarter of this year was a difficult one for Amylyx as an organization and especially for the ALS community. The top-line results from the PHOENIX trial of AMX0035 and ALS were deeply disappointing and surprising given the prior CENTAUR trial results that had showed a meaningful benefit of AMX0035 for people living with ALS and supported an FDA approval. But as a mission-driven, the next steps were clear. We moved quickly to restructure our organization in order to continue our work for one day ending the suffering caused by neurodegenerative diseases.